SYRS (Syros Pharmaceuticals) Debt-to-Equity : -5.42 (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Debt-to-Equity?

Syros Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $2.58 Mil. Syros Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $57.64 Mil. Syros Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $-11.12 Mil. Syros Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2024 was -5.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Syros Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

SYRS' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.55 Med: 0.47 Max: 4.1
Current: -5.42

During the past 10 years, the highest Debt-to-Equity Ratio of Syros Pharmaceuticals was 4.10. The lowest was -9.55. And the median was 0.47.

SYRS's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs SYRS: -5.42

Syros Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Syros Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Debt-to-Equity Chart

Syros Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.33

0.73

0.77

0.50

3.73

Syros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															1.72	3.73	4.10	-9.55	-5.42

Competitive Comparison of Syros Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Syros Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syros Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Syros Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Syros Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.991	+	53.084)	/	16.662
	=	3.73

Syros Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.584	+	57.642)	/	-11.123
	=	-5.41

Syros Pharmaceuticals (OTCPK:SYRS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Syros Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Syros Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (OTCPK:SYRS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0LC7:UK 0S90:Germany

Address

35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140

Website

https://www.syros.com

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Executives

Nancy A Simonian	director, 10 percent owner, officer: President & CEO	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk	officer: Chief Legal Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth	officer: Chief Medical Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas	officer: Chief Financial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens	officer: Chief Development Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley	officer: Chief Commercial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson	officer: Chief Scientific Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson	director	ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh	director	C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn	officer: Chief Business Officer	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421